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Abstract Docosahexaenoic acid (DHA), the end-product
of the metabolism of omega-3 family fatty acids, is the
main polyunsaturated fatty acid of the brain, but its
accumulation is incompletely understood. This paper
reviews how it could accumulate through specific uptake
of DHA-containing lysophosphatidylcholine (LysoPC-
DHA). DHA migrates very easily from the sn-2 position of
LysoPC, which could be considered as the physiological
form of polyunsaturated LysoPC, to the sn-1 position, which
is much more stable. An approach preventing migration by
acetylating the sn-1 position, while retaining the main
physico-chemical properties of the carrier, is described.
Also, the double lipoxygenation and bond-isomerization of
DHA into 10(S),17(S)-docosahexa-4Z,7Z,11E,13Z,15E,19Z-
enoic acid, named PDX, by soybean lipoxygenase is
described. As in other E,Z,E conjugated trienes, PDX is
shown to inhibit human blood platelet aggregation at
submicromolar concentrations.
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Introduction
Docosahexaenoic acid (DHA, 22:6w3) is a long-chain fatty
acid of the omega-3 family derived from the essential
precursor linolenic acid (LNA, 18:3w3). DHA is the main
end-product of LNA after successive desaturations and
elongations, a metabolic cascade that is assumed to be weak
in humans [1, 2].
DHA is mainly esterified in membrane phospholipids of
the brain, retina, and spermatozoa [3]. Its function in the
two former structures has been well documented, and it is
assumed to play an important role in brain development,
learning ability, and visual acuity. One outstanding issue,
however, remains unresolved, namely to understand how
DHA specifically accumulates in these organs, especially in
brain which is tightly separated from the blood circulation
by the blood–brain barrier.
Furthermore, DHA, being highly unsaturated, has the
potential to be oxygenated by various lipoxygenases to
produce diverse oxylipins. A pioneer work has shown that
DHA can be converted by the so-called 5-lipoxygenase
(responsible for leukotriene production from arachidonic
acid) into 7-hydroperoxy-DHA and its 7-hydroxy derivative
7-HDoHE [4]. A further report has described the formation
of both 11- and 14-hydroperoxy-DHA and their hydroxy
derivatives 11- and 14-HDoHE by platelet lipoxygenase
[5]. More recently, a series of di- and tri-hydroxy
derivatives of DHA have been described as conjugated
trienes and tetraenes derived from double or triple
oxidation. The most bioactive of these have been termed
resolvins because they promote the resolution of inflam-
mation [6] and protectin D1 (PD1) or neuroprotectin D1
(NPD1) because of a potent anti-inflammatory potential [7]
and potent neuroprotective effect [8], respectively. The
anti-inflammatory effects of these compounds could
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The present paper reports on the targeting of the brain
with DHA-containing phospholipids and on the oxygena-
tion of DHA by an omega-6 lipoxygenase, forming an
isomer of PD1 that we have named PDX.
Targeting the Brain with Choline Phospholipids
It is generally assumed that the transport of fatty acids to
the brain occurs from the non-esterified pool (NEFA)
bound to serum albumin. NEFA would then cross the
blood–brain barrier (BBB) as a result of competition
between the hydrophobic domain of albumin and that of
the endothelial layer of the BBB, as reported for other
organs [9]. However, serum albumin also binds lysophos-
pholipids, mainly lysophosphatidylcholine (LysoPC), also
called lysolecithin. It has been known for years that LysoPC
is produced by lecithin cholesterol acyl transferase as a
result of transferring, within high-density lipoproteins
(HDL), the acyl chain from the sn-2 position of HDL-PC
to free cholesterol, producing cholesterylester and LysoPC;
the latter is further transferred to albumin [10]. The
resulting LysoPC has a saturated acyl chain at the sn-1
position. However, the release of unsaturated LysoPC
resulting from the cleavage of PC by the liver phospholi-
pase A1 could not be excluded, so we have considered the
possibility that unsaturated LysoPC, including DHA-
containing LysoPC (LysoPC-DHA), can become associated
with albumin and transfer across the BBB as do NEFA.
First, a series of
14C-labeled FA (arachidonic, linoleic,
oleic, and palmitic acids), either as NEFA or esterified at
the sn-2 position of LysoPC, were bound to albumin and
injected into the rat to look at the brain accretion of each
FA. The three unsaturated FA, but not palmitic acid, were
taken up by the brain more efficiently (from 5- to 10-fold)
when in LysoPC compared to the NEFA form [11].
Secondly, DHA in both forms was injected to another set
of rats, and its incorporation into the brain, heart, kidney,
and liver was measured. Again, DHA uptake by the brain
was around 10-fold more efficient when injected as
LysoPC-DHA compared to DHA. This was specific for
the brain, since there was no preference between the
accumulation of the two forms of DHA in the kidney, and
the heart and liver even preferred DHA to Lyso PC-DHA
[12].
This approach clearly showed that LysoPC-DHA is a
privileged form of transport of DHA to the brain.
In another approach,
13C-labeled DHA esterified in
triacylglycerols (TG), the form of DHA in fish oil, was
ingested by rats, and the
13C-DHA was followed in various
blood compartments and brain phospholipids by gas-
chromatography combustion isotope ratio mass spectrome-
try. Focusing on the serum albumin pool, it could be seen
that DHA accumulated in LysoPC-DHA with only a slight
decrease over time (evaluated for 72 h), while non-
esterified DHA transiently peaked with a return to basal
by 12 h post-intake. In parallel,
13C-DHA was followed in
brain phospholipids and was found to increase in the main
glycerophospholipids/phosphatidylcholine (PC) and phos-
phatidylethanolamine, until 72 h post-intake. This fits with
the hypothesis that LysoPC-DHA, rather than non-esterified
DHA, is the main carrier of DHA transported by albumin
[13].
The same approach was then used in humans with
measurement of
13C-DHA accumulation in blood platelets
and red cells, the former compartment being known to
rapidly accumulate PUFA from the NEFA pool bound to
albumin, whereas the latter compartment is accepted as an
index of the brain DHA accretion.
The pattern for the kinetic accumulation of
13C-DHA in
serum albumin was quite similar to that observed in rats,
with a transient peak in the NEFA pool and return to basal
by 12 h post-intake, and accumulation in LysoPC with a
slow decrease over time.
The incorporation of DHA into platelet phospholipids
was rapid and attained a plateau when
13C-DHA in the
NEFA pool of albumin had returned to basal; a lag phase of
8 h followed by a constant rise until 3 days post-intake
could be seen in red cells. This is in good agreement with
LysoPC-DHA being the main source of DHA for red cells,
whereas platelets take up DHA rather uniquely from the
NEFA pool [14].
Finally,
13C-DHA esterified in PC was ingested by
humans. The kinetics of
13C-DHA in serum albumin NEFA
and LysoPC, as well in platelets and red cells, were not
markedly different from those obtained after ingestion of
13C-DHA in triacylglycerols. However, we were able to
detect LysoPC-DHA itself in red cells as additional
evidence for considering LysoPC as a main source of
DHA to red cells and in turn to the brain [15].
We then analyzed the content of human and rat plasma
for LysoPC as well as their FA composition and position on
the glycerol backbone. We found substantial amounts of
PUFA in LysoPC, with linoleic, arachidonic, and docosa-
hexaenoic acids being the main species; around 50% of the
PUFA was in the sn-2 position of the glycerol moiety.
Provided that three quarters of the DHA in the sn-2 position
migrates to the sn-1 position within 20 min at 37°C and
physiological pH7.4, this means that the main form of
production of LysoPC-DHA is the one with DHA at the sn-
2 position [16].
In summary, we came to the following scheme in which,
once absorbed at the intestinal stage, DHA may circulate in
different forms, including PC (the main circulating glycer-
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hydrolyzed by lipoprotein lipase to provide non-esterified
DHA. Part of PC-DHA could then be hydrolyzed by the so-
called endothelial lipase, which has recently been described
as selective for DHA-containing phospholipids, to release
1-lyso,2-DHA-glycerophosphocholine (LysoPC-DHA)
[17]. Both LysoPC-DHA and non-esterified DHA are
bound to albumin and could then provide DHA to the
brain, with the former being more efficient. Figure 1
summarizes this scheme.
Considering that DHA is at the sn-1 position of LysoPC,
the most stable form of LysoPC-DHA (see above) is not the
physiological form to be reacylated in the brain, because
DHA is stored in tissues at the sn-2 position; we therefore
made an attempt to keep DHA at this position. We first
blocked the alcohol function at the sn-1 position by
acetylation. This could be achieved by chemical treatment
of 1-lyso,2-DHA-glycerophosphocholine with acetic anhy-
dride [18]. The product, 1-acetyl,2-DHA-glycerophospho-
choline, has been named AceDoPC. More recently, we set
up a one-step enzymatic way to generate AceDoPC from
PC-DHA, which improved the yield of the isomer with
DHA at the sn-2 position [19] (Fig. 2). AceDoPC is
produced in order to assess its metabolism in humans (use
of
13C-labeled AceDoPC) and to test its effects on different
neurobiological disorders in rodents.
Lipoxygenation of DHA into Dihydroxylated
Conjugated Triene Derivatives
PD1 has been shown by the group of Serhan to be produced
by treatment of DHA by soybean lipoxygenase [20]. This
lipoxygenase is an omega-6 lipoxygenase, which produces
17(S)-HOO-docosahexa-4Z,7Z,10Z,13Z,15E,19Z-enoic ac-
id (17(S)-HpDoHE) from DHA, which is easily reduced
into its hydroxy derivative 17(S)-HDoHE. PD1 has been
further characterized as 10(S),17(S)-diOH-docosahexa-
4Z,7Z,11E,13E,15Z,19Z-enoic acid, assuming the formation
of an epoxide intermediate as is well known for leukotriene
B4 formation from arachidonic acid [21].
In the mean time, Butovich et al. [22] described the
formation of 10,17(S)-diOH-docosahexa-4Z,7Z,11E,13Z,
15E,19Z-enoic acid and called it PD1. However, the two
structures differ in their conjugated triene cis/trans geom-
etry, which is E,Z,E in the latter molecule while it is E,E,Z
in PD1, according to Serhan.
We have reconsidered the conversion of DHA by
soybean lipoxygenase type 1-B and found a major product
as 17(S)-HDoHE and a second one as 10(S),17(S)-diOH-
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Fig. 1 Proposed metabolism for DHA with ultimate incorporation
into brain phospholipids. DHA is weakly produced from linolenic acid
(LNA) in the liver. LysoPC-DHA may be produced from PC-DHA
hydrolysis by liver phospholipase A1 and released and/or by
endothelial lipase from circulating PC-DHA. LysoPC-DHA may be
taken up by the brain to be reacylated into PC and/or hydrolyzed to
provide DHA to be esterified into phospholipids within the brain.
Interconversion between brain phospholipids may also occur
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Fig. 2 Scheme for the preparation of AceDoPC from PC-DHA. PC-
DHA purified from the micro-algae Crypthecodinium cohnii is
submitted for transesterification by the action of an immobilized
triglyceride lipase in the presence of ethylacetate. AceDoPC is finally
purified by HPLC.
13C-Labeled DHA is prepared by cultivating the
micro-algae in the presence of
13C-labeled acetate
DHA
Omega-9 & -6 LOX
14(S)-& 17(S)-HDoHE
Omega-6 LOX 
(double oxygenation)
10(S),17(S)-diOH-DHA (PDX)
Platelet activation
Fig. 3 Inhibition of platelet activation by lipoxygenase (LOX)
products of DHA. Platelet aggregation is inhibited by monoxydroxy
derivative of DHA and by the dihydroxy derivative conjugated triene
having the E,Z,E geometry, issued from the double lipoxygenation of
DHA, called PDX, an isomer of neuroprotectin D1
50 Mol Neurobiol (2010) 42:48–51docosahexa-4Z,7Z,11E,13Z,15E,19Z-enoic acid in agree-
ment with Butovich, although this author did not determine
the stereoconfiguration of carbon 10. Our results strongly
suggest that the product we have characterized is likely to
derive from a double lipoxygenation of DHA. We have
named it PDX to differentiate it from PD1 [23].
Interestingly, PDX and other fatty acids having the E,Z,E
conjugated triene geometry are potent inhibitors of platelet
aggregation, whereas those with the E,E,Z geometry are not.
This makes the E,Z,E conjugated triene motif relevant in the
inhibition of platelet aggregation by lipoxygenase products.
These data follow previous evidence showing that
monohydroxy derivatives of DHA, produced by omega-9
and omega-6 lipoxygenases, inhibit thromboxane-induced
platelet aggregation [24], summarized in Fig. 3.
Altogether, our data show that DHA metabolites may
attenuate platelet activation, in addition to DHA competi-
tion with the arachidonic acid cascade from endogenous
phospholipids. It is conceivable that these metabolites may
also reduce inflammatory processes in neural tissues
including brain.
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